1. Home
  2. IMRN vs FEBO Comparison

IMRN vs FEBO Comparison

Compare IMRN & FEBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMRN
  • FEBO
  • Stock Information
  • Founded
  • IMRN 1994
  • FEBO 1993
  • Country
  • IMRN Australia
  • FEBO Hong Kong
  • Employees
  • IMRN N/A
  • FEBO N/A
  • Industry
  • IMRN Biotechnology: Pharmaceutical Preparations
  • FEBO
  • Sector
  • IMRN Health Care
  • FEBO
  • Exchange
  • IMRN Nasdaq
  • FEBO Nasdaq
  • Market Cap
  • IMRN 9.2M
  • FEBO 8.0M
  • IPO Year
  • IMRN N/A
  • FEBO 2023
  • Fundamental
  • Price
  • IMRN $1.85
  • FEBO $0.79
  • Analyst Decision
  • IMRN Strong Buy
  • FEBO
  • Analyst Count
  • IMRN 1
  • FEBO 0
  • Target Price
  • IMRN $5.00
  • FEBO N/A
  • AVG Volume (30 Days)
  • IMRN 41.0K
  • FEBO 447.2K
  • Earning Date
  • IMRN 08-29-2025
  • FEBO 10-24-2025
  • Dividend Yield
  • IMRN N/A
  • FEBO N/A
  • EPS Growth
  • IMRN N/A
  • FEBO N/A
  • EPS
  • IMRN N/A
  • FEBO N/A
  • Revenue
  • IMRN $4,777,422.00
  • FEBO $17,110,653.00
  • Revenue This Year
  • IMRN N/A
  • FEBO N/A
  • Revenue Next Year
  • IMRN N/A
  • FEBO N/A
  • P/E Ratio
  • IMRN N/A
  • FEBO N/A
  • Revenue Growth
  • IMRN 48.63
  • FEBO 11.58
  • 52 Week Low
  • IMRN $1.50
  • FEBO $0.61
  • 52 Week High
  • IMRN $2.87
  • FEBO $7.26
  • Technical
  • Relative Strength Index (RSI)
  • IMRN 52.64
  • FEBO 52.25
  • Support Level
  • IMRN $1.80
  • FEBO $0.75
  • Resistance Level
  • IMRN $1.94
  • FEBO $0.84
  • Average True Range (ATR)
  • IMRN 0.08
  • FEBO 0.06
  • MACD
  • IMRN -0.01
  • FEBO 0.01
  • Stochastic Oscillator
  • IMRN 48.76
  • FEBO 71.96

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

About FEBO Fenbo Holdings Limited

Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.

Share on Social Networks: